Key Facts

PIPS Key Facts
Active Substance
Active Substance:
  • bimekizumab
Invented Name
Not yet available
PIP Number MHRA-100022-PIP01-21
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Solution for injection
Therapeutic area
  • Immunology -Rheumatology-Transplantation
  • Dermatology
Conditions / Indications
Conditions / Indications:
  • Hidradenitis suppurativa
Route(s) of administration
Route(s) of administration:
  • Subcutaneous use
PIP applicant
Decision Type
Decision Type
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)
Compliance Check
Compliance Check
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Bimekizumab.pdf
Published Date 17/11/2021